The deal inside the deal: what AkzoNobel and Axalta must sell before they can merge

Two of the world's largest coatings makers can now merge in Europe, but only after they sell something first. On 6 November the European Commission cleared the combination of AkzoNobel and Axalta on condition that AkzoNobel's vehicle refinish business in the European Economic Area goes to an approved buyer before the merger is implemented. Five days later the UK's Competition and Markets Authority found the same overlap in the UK market. The lesson for anyone selling to, or buying from, a strategic acquirer is simple: when a deal needs a remedy, the remedy becomes a transaction of its own, with its own buyer, its own price and its own clock.

What the regulators found

The deal is an all-stock combination of the Dutch paint group and the US coatings maker, announced in November 2025 and valued at about $25 billion. The concern was narrow: the paint that body shops use to repair damaged cars.

The Commission's description of the market explains why. To match the colour of an aged vehicle, garages scan the paint and match it against colour databases, using equipment supplied by the coatings maker. That makes switching suppliers hard. The four largest suppliers account for up to 80-90% of sales across the EEA, Axalta is the market leader and AkzoNobel the fourth largest, and every other supplier has an EEA-wide share below 5%. The Commission also found the parties' claimed efficiencies "not sufficiently substantiated".

In London the CMA reached a similar view on 11 November. It found a realistic prospect of a substantial lessening of competition in UK vehicle refinish coatings, where the merged company would be the clear market leader with a combined share of supply of 40-50%. It cleared the other overlap it examined, thermosetting powder coatings, because customers multi-source and enough rivals remain. The parties have until 18 November to offer undertakings. Otherwise the merger goes to an in-depth Phase 2 investigation. The companies say they will offer the same remedy accepted in Brussels and still expect to complete in early 2027.

A remedy is a carve-out with a regulator in the room

The commitments describe a full standalone business: a dedicated manufacturing site able to handle the same volumes, the related assets, transitional services agreements, intellectual property and staff. The buyer must already be active in coatings or be an industrial player in a related industry. An independent trustee will monitor the process, and the Commission will vet the proposed buyer in a separate approval procedure.

The merger cannot close until a regulator approves who buys the piece it does not want.

That clause, known as an upfront buyer requirement, moves the critical path. The timetable no longer depends only on regulators reviewing the main deal. It depends on finding a buyer who is credible to the authority, who can fund the purchase and who will sign on terms the seller can live with. The seller's negotiating position is weaker than in an ordinary sale: the market knows the business must go and roughly when.

For a strategic buyer of a privately held company, the same mechanics apply at smaller scale. Where the buyer already competes with the target in a concentrated niche, a divestiture may be the price of clearance, and the business to be sold may be the buyer's own or part of the target.

Who carries the risk

For a private seller, the commercial question is who bears the cost of a remedy and the delay it brings. The usual tools are an obligation on the buyer to accept remedies up to a defined limit, an outside date with room for a Phase 2 review, and a reverse break fee if clearance fails. Each one is only as useful as its drafting. A cap expressed as "any divestiture" means something different from a cap measured by revenue or by named assets.

For buyers of remedy assets, a forced sale can be an opportunity, but it comes with constraints. The buyer criteria narrow the field, the regulator will test the buyer's plan, and the business often arrives with transitional services from a seller that is also its largest competitor. Diligence has to cover separation as much as performance: supply agreements, customer approvals and the equipment installed at customer sites.

Questions to ask

• If your buyer competes with you anywhere, which markets could draw a remedy, and how large could it be?
• Does the agreement say who must offer divestitures, up to what limit, and who chooses the buyer?
• Does the outside date leave room for an upfront buyer process and a possible Phase 2 review?
• Are the review timetables in different jurisdictions aligned, or can one authority hold the deal while another has cleared it?
• If you are buying a remedy business, what will it still depend on its former owner for, and for how long?

Sources

• European Commission: Commission approves merger between AkzoNobel and Axalta, subject to conditions (6 November 2026)
• CMA: AkzoNobel / Axalta merger inquiry, case page
• CMA: Summary of Phase 1 decision (11 November 2026)
• AkzoNobel: Update on the UK CMA's review of the AkzoNobel-Axalta merger (11 November 2026)
• AkzoNobel and Axalta joint release on EU clearance, SEC Form 6-K (6 November 2026)
• PYMNTS: EU clears $25 billion AkzoNobel-Axalta merger with antitrust conditions